(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 40.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Alnylam Pharmaceuticals's revenue in 2025 is $2,461,963,000.On average, 13 Wall Street analysts forecast ALNY's revenue for 2025 to be $456,613,486,594, with the lowest ALNY revenue forecast at $438,552,371,276, and the highest ALNY revenue forecast at $500,590,758,285. On average, 13 Wall Street analysts forecast ALNY's revenue for 2026 to be $664,788,852,610, with the lowest ALNY revenue forecast at $503,555,765,604, and the highest ALNY revenue forecast at $997,458,872,544.
In 2027, ALNY is forecast to generate $890,377,672,531 in revenue, with the lowest revenue forecast at $706,395,298,156 and the highest revenue forecast at $1,388,782,163,925.